AcouSort

2.71 SEK

-3.21 %

Less than 1K followers

ACOU

First North Stockholm

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-3.21 %

-2.17 %

-13.97 %

-20.29 %

-75.36 %

-74.19 %

-86.13 %

-87.15 %

-65.66 %

AcouSort operates in the medical technology sector. The company has a developed platform technology focused on acoustophoresis, which uses ultrasound to separate and analyze the compositions of biological cells. The technology is mainly used in the analysis of cancer cases and sepsis (blood poisoning). A large part of the research is carried out in collaboration with other players in Life Science. The company was established in 2010 and has its headquarters in Lund.

Market cap

57.35M SEK

Turnover

125.07K SEK

Revenue

4.74M

EBIT %

-340.3 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

25.2

2026

Annual report '25

All

Press releases

ShowingAll content types

Press release11/27/2025, 1:06 PM

Redeye: AcouSort (Q3 review) - New collaboration alongside progress in existing one

Regulatory press release11/26/2025, 5:55 AM

AcouSort AB - Interim Report for the period January - September 2025

Press release11/19/2025, 9:45 AM

AcouSort and Danish SeeQ Diagnostics sign technology evaluation agreement

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release9/22/2025, 8:40 AM

AcouSort receives new order boosting Central European collaboration

Press release9/17/2025, 11:30 AM

AcouSort to present at Redeye’s theme event Tools and Supplies in Life Science 2025

Press release9/15/2025, 1:45 PM

AcouSort invited to present at 10th Bioproduction congress in Lyon

Regulatory press release9/3/2025, 7:00 AM

AcouSort AB changes Certified Adviser to Tapper Partners AB

Press release8/28/2025, 8:30 AM

Redeye: AcouSort Q2 - Robust cost control

Regulatory press release8/27/2025, 5:00 AM

AcouSort AB - Interim Report for the period January - June 2025

Press release7/28/2025, 6:30 AM

AcouSort’s AcouWash technology enables centrifuge-free cell radiolabeling using acoustophoresis

Regulatory press release6/25/2025, 10:25 AM

Communiqué from the annual general meeting of AcouSort AB (publ)

Press release6/13/2025, 11:05 AM

AcouSort selected for panel participation at BIO 2025

Press release5/30/2025, 11:19 AM

Redeye: AcouSort Q1 - In line with estimates

Regulatory press release5/28/2025, 5:00 AM

AcouSort AB - Interim Report for the period January - March 2025

Regulatory press release5/28/2025, 5:00 AM

AcouSort AB - Annual report 2024

Press release5/21/2025, 10:00 AM

AcouSort strengthens Central European collaboration with new order

Regulatory press release5/14/2025, 12:00 PM

AcouSort’s rights issue is registered – conversion of BTA into shares

Regulatory press release5/6/2025, 6:15 PM

AcouSort announces final outcome in the rights issue

Regulatory press release5/5/2025, 6:00 PM

AcouSort announces preliminary outcome of rights issue

Regulatory press release4/29/2025, 6:30 AM

Last day of trading in subscription rights in AcouSort

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.